Abstract: The present invention is to provide a drug for analysis of a water transport function of a membrane protein in a biological tissue, wherein the abundance of one or both of 17O water molecules or 18O water molecules in the drug is greater than their abundance in natural water. Furthermore, the present invention is to provide a method of analysis of a water transport function of a membrane protein in a biological tissue, a usage of the drug for analysis of a water transport function, and a method of diagnosis diagnosing pathologies caused by abnormalities of the water transport function.

Abstract: The present invention is to provide a drug for analysis of a water transport function of a membrane protein in a biological tissue, wherein the abundance of one or both of 17O water molecules or 18O water molecules in the drug is greater than their abundance in natural water. Furthermore, the present invention is to provide a method of analysis of a water transport function of a membrane protein in a biological tissue, a usage of the drug for analysis of a water transport function, and a method of diagnosis diagnosing pathologies caused by abnormalities of the water transport function.

Abstract: A highly purified metal complex with an amino-oligosaccharide derivative is produced by effectively removing impurities, by-products, excess salts and the like that have been produced during the reaction steps for synthesis of the amino-oligosaccharide derivative and the steps for formation of its metal complexes. A process for producing a metal complex with an amino-oligosaccharide derivative is provided, in which a crude reaction liquid containing an amino-oligosaccharide derivative is subjected to a complexation process with a metal ion and a purification process, and the purification process comprises at least one step by a solvent extraction process, an anion exchange process, a membrane filtration process, an electrodialysis process or an adsorption process.

Abstract: There is disclosed a diagnostic imaging agent which comprises a compound wherein at least one bifunctional ligand is chemically bonded to an amino group of amino oligosaccharide having the molecular weight of 500 to 2000 and having a reduction-treated reducing end of a sugar chain, or to an aldehyde group of a dialdehyde-oligosaccharide, at least one constituent monosaccharide of which is oxidation-cleaved, having the molecular weight of 500 to 2000 and having a reduction-treated reducing end of a sugar chain, and said ligand is coordinated with at least one metal ion selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.

Abstract: There is disclosed an imaging agent for diagnosis comprising a compound composed of a polynuclear type compound of the formula I or II: ##STR1## wherein each X is a hydrogen atom or a bifunctional ligand, at least one of them are bifunctional ligand and m or n is an integer of 1 to 6, and at least one metal ion being coordinated with at least one bifunctional ligand moiety, said metal ion being selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.

Abstract: There is disclosed an imaging agent for diagnosis comprising a compound composed of a polynuclear type compound of the formula I or II: ##STR1## wherein each X is a hydrogen atom or a bifunctional ligand, at least one of them are bifunctional ligand and m or n is an integer or 1 to 6, and at least one metal ion being coordinated with at least one bifunctional ligand moiety, said metal ion being selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.

Abstract: There is disclosed a nuclear magnetic resonance imaging agent comprising a complex compound composed of (a) a dialdehyde-saccharide having a molecular weight of from 500 to 10,000, at least one of the constituent monosaccharides of which is oxidation-cleaved, (b) at least one complexing agent which is chemically coupled to an aldehyde group of the dialdehyde-saccharide and (c) a paramagnetic metal ion which is chemically coupled to the complexing agent.

Abstract: There is disclosed an imaging agent for diagnosis comprising a compound composed of a polynuclear type compound of the formula I or II: ##STR1## wherein each X is a hydrogen atom or a bifunctional ligand, at least one of them are bifunctional ligand and m or n is an integer of 1 to 6, and at least one metal ion being coordinated with at least one bifunctional ligand moiety, said metal ion being selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.